Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
198
datasets available to search
ShareScore release 0.9.0
Dataset results
198 results for “Colorectal Carcinoma”
Drug-drug interactions of irinotecan, 5-fluorouracil, folinic acid and oxaliplatin for improved colorectal carcinoma treatment
<p>Research records and experimental data of the study "Drug-drug interactions of irinotecan, 5-fluorouracil, folinic acid and oxaliplatin for improved colorectal carcinoma treatment"</p>
Dataset Friebus-Kardash et al, A chemerin peptide analog stimulates tumor growth in two xenograft mouse models of human colorectal carcinoma
<p>Dataset Friebus-Kardash et al, A chemerin peptide analog stimulates tumor growth in two xenograft mouse models of human colorectal carcinoma</p> <p> </p>
Hepatocellular carcinoma (HCC) Tumor microenvironment is more suppressive than colorectal cancer liver metastasis (CRLM) Tumor microenvironment.
<p><strong>Background and purpose:</strong> While HCC is an inflammation-associated cancer, CRLM develop on permissive healthy liver microenvironment. To evaluate the immune aspects of these two different environments, peripheral blood-(PB), peritumoral-(PT) and tumoral tissues-(TT) from HCC and CRLM patients were evaluated.</p> <p><strong>Methods:</strong> 40 HCC and 34 CRLM were enrolled and freshly TT, PT and PB were collected at the surgery. PB-, PT- and TT-derived CD4<sup>+</sup>CD25<sup>+ </sup>Tregs, M/PMN-MDSC and PB-derived CD4<sup>+</sup>CD25<sup>− </sup>Teffector cells (Teffs) were isolated and characterized. Tregs function was also evaluated in the presence of the CXCR4 inhibitor, Peptide-R29, AMD3100 or anti-PD1. RNA was extracted from PB/PT/TT-tissues and tested for FOXP3, CXCL12, CXCR4, CCL5, IL-15, CXCL5, Arg-1, N-cad, Vim, CXCL8, TGFβ and VEGF-A expression.</p> <p><strong>Results:</strong> In HCC/CRLM-PB higher number of functional Tregs, CD4<sup>+</sup>CD25<sup>hi</sup>FOXP3<sup>+</sup> were detected, although PB-HCC Tregs exert a more suppressive function as compared to CRLM-Tregs. In HCC/CRLM-TT Tregs were highly represented with Activated/ENTPD-1<sup>+</sup>Tregs prevalent in HCC. As compared to CRLM, HCC overexpressed CXCR4 and N-cadherin/Vimentin in a contest rich of arginase and CCL5. Monocytic-MDSCs were highly represented in HCC/CRLM while high Polymorphonuclear-MDSCs were detected only in HCC. Interestingly, CXCR4-PB-Tregs function was impaired in HCC/CRLM by the CXCR4 inhibitor R29.</p> <p><strong>Conclusion:</strong> In HCC and CRLM, peripheral blood, peritumoral and tumoral tissues-Tregs are highly represented and functional. Nevertheless, HCC display a more immunosuppressive TME due to Tregs, MDSCs, intrinsic tumor features (CXCR4, CCL5, arginase) and the contest in which it develops. As CXCR4 is overexpressed in HCC/CRLM tumor/TME cells, CXCR4 inhibitors may be considered for double hits therapy in liver cancer patients.</p>
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas
ClinicalTrials.gov study NCT00923481. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Clinical Trial to Evaluate Safety and Efficacy of Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) With Mitomycin C Used During Surgery for Treatment of Locally Advanced Colorectal Carcinoma
ClinicalTrials.gov study NCT02614534. IPD Sharing: YES. Countries: 1. Publications: 2.
BBI608 and Best Supportive Care vs Placebo and Best Supportive Care in Pretreated Advanced Colorectal Carcinoma
ClinicalTrials.gov study NCT01830621. IPD Sharing: NO. Countries: 3. Publications: 1.
Randomized Phase II Adjuvant Chemotherapy ± FANG™ in Colorectal Carcinoma With Liver Metastases
ClinicalTrials.gov study NCT01505166. IPD Sharing: Not stated. Countries: 1. Publications: 7.
Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)
ClinicalTrials.gov study NCT05061017. IPD Sharing: NO. Countries: 1. Publications: 1.
RAD001, FOLFOX and Bevacizumab in Treatment of Colorectal Carcinoma
ClinicalTrials.gov study NCT01047293. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Physical Activity for Reduction of Recurrence Rate After Adjuvant Chemotherapy for Localised Colorectal Carcinoma
ClinicalTrials.gov study NCT01210313. IPD Sharing: Not stated. Countries: 1. Publications: 6.
MK-2206 and AZD6244 in Patients With Advanced Colorectal Carcinoma
ClinicalTrials.gov study NCT01333475. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Study of Modified FOLFOX6 Plus or Minus Sorafenib in Stage IV Metastatic Colorectal Carcinoma (mCRC) Subjects
ClinicalTrials.gov study NCT00865709. IPD Sharing: Not stated. Countries: 10. Publications: 1.
Mapping and modeling human colorectal carcinoma interactions with the tumor microenvironment
<p>This dataset can be interactively explored with VisCello (https://github.com/qinzhu/VisCello). Please install VisCello and use e.g. "cello("path_to/hcc_main_cello")" to load the human colon cancer single cell dataset.</p> <p> </p>
Pembrolizumab With Ataluren in Patients With Metastatic pMMR and dMMR Colorectal Carcinoma or Metastatic dMMR Endometrial Carcinoma: the ATAPEMBRO Study
ClinicalTrials.gov study NCT04014530. IPD Sharing: NO. Countries: 1. Publications: 2.
Phase II Study of the Role of Anti-CEA Antibody Immunoscintigraphy & Positron Emission Tomography in the Localization of Recurrent Colorectal Carcinoma in Patients With Rising Serum CEA Levels in the
ClinicalTrials.gov study NCT00001568. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Study of Guanábana Leaves for The Treatment of Patients With Gastric, Gastroesophageal Junction, Pancreatic and Colorectal Adenocarcinomas; Hepatocellular Carcinoma, and Low Grade Lymphomas
ClinicalTrials.gov study NCT04773769. IPD Sharing: UNDECIDED. Countries: 1. Publications: 15.
L-BLP25 in Patients With Colorectal Carcinoma After Curative Resection of Hepatic Metastases
ClinicalTrials.gov study NCT01462513. IPD Sharing: Not stated. Countries: 2. Publications: 1.
Study of TCM Syndrome of Hepatocellular Carcinoma and Colorectal Cancer Based on System Science
ClinicalTrials.gov study NCT03189992. IPD Sharing: UNDECIDED. Countries: 1. Publications: 3.
Laparoscopic Assisted Versus Open Resection for Colorectal Carcinoma
ClinicalTrials.gov study NCT00485316. IPD Sharing: Not stated. Countries: 1. Publications: 2.
A Phase 2 Study of Tomudex & Iressa as Second Line Chemotherapy in Subjects With Colorectal Carcinoma
ClinicalTrials.gov study NCT00234429. IPD Sharing: Not stated. Countries: 1. Publications: 3.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.